Report Overview:
BNCT (Boron Neutron Capture Therapy) drugs are specialized pharmaceutical compounds containing boron-10 isotopes that selectively accumulate in tumor cells. When irradiated with thermal neutrons, these drugs undergo nuclear reactions that destroy cancer cells while minimizing damage to surrounding healthy tissue. The two primary types include small molecule boron drugs and boron-bound biological complexes, with applications targeting various cancers including glioblastoma, head & neck cancers, and melanoma.
The market growth is driven by increasing oncology R&D investments, rising cancer prevalence (with WHO reporting 20 million new cases annually), and advancements in targeted radiation therapies. However, challenges include high treatment costs and limited neutron source facilities globally. Key developments include STELLA PHARMA's 2023 approval of Steboronine in Japan for recurrent head and neck cancer, marking the first commercial BNCT drug. The Asia-Pacific region currently dominates the market, accounting for over 60% of global revenue, primarily due to Japan's leadership in BNCT clinical applications.
Market Value:
Global BNCT Boron Drug market size was valued at USD 72 million in 2024. The market is projected to grow from USD 82 million in 2025 to USD 160 million by 2032, exhibiting a CAGR of 12.3% during the forecast period.
By Applications:
Head and Neck Cancer (Recurrent)
Glioblastoma Multiforme
Melanoma
Prostate Cancer
Others
By Types:
• Small Molecule Boron Drugs
• Boron-bound Biological Complexes
Key players include:
• STELLA PHARMA CORPORATION (Japan)
• TAE Life Sciences (U.S.)
• Japanese Society of Neutron Capture Therapy (JSNCT)
• Chongqing Gaojin Biotechnology Co., Ltd. (China)
